HC Wainwright assumed coverage on shares of Entasis Therapeutics (NASDAQ:ETTX) in a research report report published on Monday, 24/7 WallStreet reports. The brokerage issued a buy rating and a $18.00 price target on the stock.
Other equities analysts have also recently issued reports about the company. Zacks Investment Research cut Entasis Therapeutics from a buy rating to a hold rating in a report on Monday, May 20th. ValuEngine raised Entasis Therapeutics from a hold rating to a buy rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $16.75.
Shares of Entasis Therapeutics stock opened at $8.32 on Monday. Entasis Therapeutics has a one year low of $3.97 and a one year high of $13.70. The stock’s fifty day moving average is $6.75 and its 200 day moving average is $6.49. The company has a quick ratio of 9.11, a current ratio of 9.11 and a debt-to-equity ratio of 0.03.
An institutional investor recently bought a new position in Entasis Therapeutics stock. BlackRock Inc. acquired a new stake in shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 13,755 shares of the company’s stock, valued at approximately $56,000. BlackRock Inc. owned approximately 0.11% of Entasis Therapeutics as of its most recent SEC filing. 65.08% of the stock is currently owned by institutional investors.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Recommended Story: Operating Income
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.